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Background: Pathogenic autoantibodies targeting the recently identified leucine rich glioma inactivated 1 protein
and the subunit 1 of the N-methyl-D-aspartate receptor induce autoimmune encephalitis. A comparison of brain
metabolic patterns in 18F-fluoro-2-deoxy-d-glucose positron emission tomography of anti-leucine rich glioma
inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis patients has not been performed yet and
shall be helpful in differentiating these two most common forms of autoimmune encephalitis.
Methods: The brain 18F-fluoro-2-deoxy-d-glucose uptake from whole-body positron emission tomography of six
anti-N-methyl-D-aspartate receptor encephalitis patients and four patients with anti-leucine rich glioma inactivated
1 protein encephalitis admitted to Hannover Medical School between 2008 and 2012 was retrospectively analyzed
and compared to matched controls.
Results: Group analysis of anti-N-methyl-D-aspartate encephalitis patients demonstrated regionally limited
hypermetabolism in frontotemporal areas contrasting an extensive hypometabolism in parietal lobes, whereas the
anti-leucine rich glioma inactivated 1 protein syndrome was characterized by hypermetabolism in cerebellar, basal
ganglia, occipital and precentral areas and minor frontomesial hypometabolism.
Conclusions: This retrospective 18F-fluoro-2-deoxy-d-glucose positron emission tomography study provides novel
evidence for distinct brain metabolic patterns in patients with anti-leucine rich glioma inactivated 1 protein and
anti-N-methyl-D-aspartate receptor encephalitis.
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Limbic encephalitis involving the temporomedial lobes
and amygdalae is characterized by subacute memory im-
pairment, seizures and neuropsychiatric symptoms with
variable evidence of cerebrospinal fluid inflammation,
anti-neuronal antibodies and a paraneoplastic origin [1-4].
The two most common targets of encephalitis associ-
ated pathogenic autoantibodies are the recently identified
leucine rich glioma inactivated 1 protein (LGI1), which is
extracellularly complexed with voltage-gated potassium
channels (VGKC), and the subunit 1 (NR1) of the N-
methyl-D-aspartate (NMDA) receptor [5-8]. LGI1 anti-
bodies associated with limbic encephalits specifically
inhibited the ligand-receptor interaction between LGI1
and ADAM22 (disintegrin and metalloproteinase domain-
containing protein 22) and reversibly reduced synaptic
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid) receptor clusters in rat hippocampal neurons [9].
Cerebrospinal fluid samples or purified immunoglobulin
G (IgG) from patients with anti-NMDA receptor enceph-
alitis led to a marked reduction of NR1 (and NR2B) sur-
face expression and NMDA receptor mediated currents in
hippocampal cultures [10,11] as well as to increased corti-
comotor hyperexcitability in rats [12,13].
While the anti-LGI1 syndrome predominantly reminds
of a classic limbic encephalitis with amnesia, (faciobrachial
dystonic) seizures and psychiatric manifestations, the anti-
NMDA receptor encephalitis is characterized by memory
deficits, psychiatric symptoms with psychotic and catatonic
features, language disintegration, dyskinetic movements,
seizures, decreased consciousness, autonomic and breath-
ing instability that often requires intensive care treatment
[6,7,13-15]. However, there may be clinical overlaps of the
two entities. A tumor association is infrequently found in
the anti-LGI1 syndrome, whereas ovarian or other tera-
toma were diagnosed in up to 50% of anti-NMDA receptor
encephalitis patients [4,6,13,16].
In order to detect underlying tumor manifestations,
whole-body 18F-fluoro-2-deoxy-d-glucose positron emis-
sion tomography (FDG-PET) is performed in many patients
with limbic encephalitis, whereby cerebral FDG uptake
can also be determined. Some case reports have published
FDG-PET data showing brain metabolic abnormalities of
varying degree and localization in adult patients with anti-
LGI1 [17] or anti-NMDA receptor encephalitis [16,18-22].
Recently, an FDG-PET study revealed a frontal and
temporal hypermetabolism associated with occipital hy-
pometabolism in six patients with anti-NMDA receptor
encephalitis [23], while a hypermetabolism in the medial
temporal lobes and basal ganglia was detected in ten anti-
LGI1 encephalitis patients [24]. The aim of our study was
to compare cerebral FDG uptake of whole-body FDG-PET
imaging in patients with anti-LGI1 and anti-NMDA re-
ceptor encephalitis for detailed analysis of brain metabolicdisease patterns that may lead to an improved diagnos-
tic accuracy.Methods
Patients and controls
We obtained an approval from the local Ethics Committee
of Hannover Medical School (No. 1625–2012) and pa-
tients or their carers gave their written informed consent.
The brain FDG uptake from whole-body FDG-PETs of
six anti-NMDA receptor encephalitis patients (6 females,
median age 36.5, interquartile range 30.5-47.25, Table 1)
and four anti-LGI1 encephalitis patients (4 males; me-
dian age 68.0, interquartile range 61–72.75, Table 2) ad-
mitted to Hannover Medical School between 2008 and
2012 was retrospectively analyzed.
Diagnostic criteria were the above mentioned typical clin-
ical symptoms of limbic encephalitis and detection of either
anti-LGI1 or anti-NMDA receptor IgG titer in serum or
cerebrospinal fluid (CSF) of at least 1:10. Antibody detec-
tion was performed using Mosaik Biochips (Euroimmun,
Lübeck, Germany) as described previously [25]. The clinical
severity at the time of PET investigation and follow up was
staged using the modified Rankin Scale (mRS). All patients
with anti-LGI1 syndrome but only one patient with anti-
NMDA receptor encephalitis were able to lie quietly in the
PET scanner, therefore, five of the latter patients had to be
investigated in propofol narcosis. The patient imaging data
were compared to separate age and sex matched control
groups without neuropsychiatric diseases who received PET
due to an extracerebral neoplasm (anti-NMDA controls: 5
females, median age 40.0, interquartile range 37.5-46, anti-
LGI1 controls: 4 males/2 females, median age 61.0, inter-
quartile range 58.75-64.5). All controls were investigated
without narcosis using the same PETacquisition protocol.FDG-PET
For positron emission tomography a Biograph LSO Duo
PET/CT (Siemens, Erlangen, Germany) was used. One
hour before scanning 350 MBq 18F-fluoro-2-deoxy-d-glu-
cose (FDG) were injected intravenously. In patients not
able to avoid movements during the scan while awake,
anesthesia was started shortly before imaging, i.e. after a
sufficient uptake phase of FDG. First a whole body low-
dose computed tomography (CT)-scan was acquired from
the mid-tight to the head using adjusted tube current (Care
Dose4D). Subsequently emission scanning was performed
in 3D mode typically over 8 bed positions of 4 minutes
each. For the present study brain images were recon-
structed separately with a matrix size of 256 × 256 and zoom
factor 2 using a 2D OSEM (ordered subset expectation
maximization) algorithm with 4 iterations and 8 subsets,
smoothing with a 5-mm FWHM (full width at half max-
imum) filter and applying CT based attenuation correction.
Table 1 Clinical, diagnostic and treatment data of patients with anti-N-methyl-D-aspartate receptor encephalitis
Patient number 1 2 3 4 5 6
Psychiatric symptoms ++ ++ + + + ++
Generalized Seizures ++ ++ ++ + + +
Serum anti-NMDA receptor
IgG titer
1:320 1:1000 - 1:1000 1:800 -
CSF anti-NMDA receptor IgG
titer
1:10 1:100 1:10 - 1:100 1:100
CSF leukocytes/μl 154 2 27 2 270 19
CSF oligoclonal bands + + - + + +
MRI lesions Hippocampal T2-hyper-intensities +
bilateral diffusion elevation
- unspecific Subcortical T2-hyper-intensities +
contrast enhance-ment
- -
Clinical onset to PET and
treatment in months
1 4 1 15 4 7
mRS at time of PET 5 5 5 4 4 3
PET in propofol narcosis + + + + + -
Intensive care treatment + + + - + -
Methylprednisolone + + + + + +
Plasmapheresis + + - + + -
Immunoglobulins + + + - - -





Oophorectomy + + + + + -
Ovarian teratoma + + - - - -
mRS at follow up (months
after PET)
4 1 1 4 1 0
(40) (40) (28) (8) (16) (36)
Abbreviations: Azathioprine (Azathiopr.), Cyclophosphamide (Cycloph.), cerebrospinal fluid (CSF), computed tomography (CT), positron emission tomography (PET),
immunoglobulin G (IgG), magnet resonance imaging (MRI), modified Rankin Scale (mRS), N-methyl-D-aspartate (NMDA), Rituximab (Rituxim.).
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analysis
Brain images were spatially normalized into the stereotatic
standard space according to Montreal Neurological Insti-
tute using the Statistical parametric mapping 2 (SPM2)
FDG brain template with default parameter settings (stat-
istical parametric mapping, Wellcome Trust Centre for
Neuroimaging, London, UK). Thereafter each data set was
smoothed with an isotropic 3D Gaussian filter kernel with
10-mm FWHM. In group comparisons (e.g. patients vs.
controls) proportional scaling to the cerebral global mean
was employed and the two sample t-test to detect voxels/
regions with either decreased or increased FDG uptake i.e.
glucose metabolism. In single-subject analyses effects were
assessed for each patient individually. Moreover, antibody
titers and clinical scores were correlated to glucose metab-
olism as covariates at a group level. Statistical inferences
were based on a p-value of 0.005 uncorrected for multiple
comparisons and an extent threshold of 30 voxels. We
additionally performed group analyses using pons and
motor cortex as reference region for scaling leading to es-
sentially the same results. For spatial assignment of signifi-
cant changes in SPM analyses volume of interest (VOI)templates according to Cyceron or reflecting Brodmann
areas were used. In order to detect changes in larger brain
regions, small VOIs according to Cyceron were summa-
rized to large VOIs (Additional file 1: Table S1) and statis-
tical analyses for group differences (t-test) and correlations
(linear regression analysis) were performed using JMP10
software (SAS Institute). A p-value < 0.05 was used for
statistical inferences.
Results
Patient and magnet resonance imaging properties
The demographic and clinical data of patients as well as
their diagnostic procedures and therapy are summarized
in Tables 1 and 2. The variability of PET time points in
anti-NMDA encephalitis patients was caused mainly by
late admission to Hannover Medical School in the dis-
ease course of some patients, however, 5/6 patients were
considered to be at the clinical peak of encephalitis at
the time of PET. They presented with typical signs and
symptoms including generalized seizures which were
treated successfully with antiepileptic drugs before PET
investigation. At the time of PET the electroencephalog-
raphy (EEG) did not record epilepsy specific potentials
Table 2 Clinical, diagnostic and treatment data of patients with anti-leucine rich glioma inactivated 1 protein
encephalitis
Patient number 1 2 3 4
Psychiatric symptoms - + - -




Focal Seizures + (dystonic faciobrachial) + + + (dystonic
faciobrachial)
Anti-LGI1 IgG titer in serum 1:100 1:100 1:100 1:100
Anti-LGI1 IgG titer in CSF - - - -
CSF leukocytes/μl 2 3 2 2
CSF oligoclonal bands - - - -
MRI lesions unspecific bitemporal T2-
hyperintensities
- -
Clinical onset to PET and treatment in
months
6 1 12 2
mRS at time of PET 2 2 2 2
PET in narcosis - - - -
Evidence of Tumor - - - -
Intensive care treatment - - - -
Methylprednisolone + + + +
Plasmapheresis + (3 months interval) + + -
Immunoglobulins - - + +
Immunosuppressive therapy - - Cyclophospha-
mide
-
mRS at follow up (months after PET) 1 0 3 0
(31) (24) (9) (18)
Abbreviations: Cerebrospinal fluid (CSF), positron emission tomography (PET), immunoglobulin G (IgG), leucine rich glioma inactivated 1 protein (LGI1), magnet
resonance imaging (MRI), modified Rankin Scale (mRS).
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and 5 (median 4.5, interquartile range 3.75-5.0, n = 6).
PET metabolic abnormalities of anti-NMDA receptor
encephalitis patients did not correspond to magnet reson-
ance imaging (MRI) lesions that were shown in 4/6
patients: Hippocampal T2-hyperintensities bilaterally with
diffusion elevation (patient 1, Figure 1A-B), small single
unspecific left paraventricular T2-hyperintensity without
contrast enhancement or diffusion restriction (patient 3),
multiple very small subcortical T2-hyperintensities with
T1-contrast enhancement (patient 4) and faint T2-
hyperintensities in both cingular gyri without contrast
enhancement (patient 5). In patients 2 and 6 MRI did not
display any lesions.
Although ovarian PET and ultrasound were unsuspi-
cious, an exploratory oophorectomy [6,26,27] was initiated
in 5/6 patients (mRS ≥ 4) after the consent of the caring
person had been obtained. Histopathologically a micro-
scopic mature ovarian teratoma containing neuronal tissue
was detected in 2/5 patients. Clinical outcome at the
last follow up after 8–40 months (mRS median 1.0,interquartile range 0.75-4.0, n = 6) was good with mRS
0–1 (4/6) or showed improvement to a moderate degree
(1/6), while one patient did not respond to treatment.
Patients with anti-LGI1 syndrome presented with symp-
toms of a classic limbic encephalitis including cognitive
deficits and focal seizures. Two patients showed faciobra-
chial dystonic seizures that were treated successfully with
methylprednisolone and antiepileptic therapy [28]. Rou-
tine EEG at the time of PET did not record epilepsy
specific potentials. PET tumor screening was negative for
neoplasia within a range of 1–12 months after clinical
onset, which corresponds to the time from onset to treat-
ment initiation. Again this variability of time points was
caused by late admission of two patients to Hannover
Medical School, however, 3/4 patients were at the clinical
peak of the anti-LGI1 encephalitis at the time of PET with
a mRS of 2.
PET abnormalities of anti-LGI1 syndrome patients did
not correspond to their MRI lesions that were not enhan-
cing after gadolinium application: Multiple microangio-
pathic T2-hyperintensities in the subcortical white matter
Figure 1 Magnet resonance imaging in anti-N-methyl-D-aspartate receptor and anti-leucine rich glioma inactivated 1 protein encephalitis
patients. Magnet resonance images from patient 1 with anti-N-methyl-D-aspartate receptor encephalitis (A-B) and patient 2 with anti-leucine rich
glioma inactivated 1 protein syndrome (C-D) are shown. In the top row (A - axial T2w-fluid attenuated inversion recovery image, B - coronal T1
weighted image with contrast enhancement) bilateral T2w-fluid attenuated inversion recovery signal hyperintensities of the corpus amygdaloideum
and of the right hippocampus (arrows) are demonstrated. There is no contrast enhancement in the area of the T1w-signal drop of the medial temporal
lobe bilaterally (b, arrows). In the bottom row (C – axial and d – coronal T2w-fluid attenuated inversion recovery image) there is a marked T2w-fluid
attenuated inversion recovery hyperintensity of the left medial temporal lobe (C – arrow), which also extends to the hippocampus (D – arrow).
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Figure 1C-D). At the time of PET, the MRI of patient 3
had not displayed any lesions yet, while we detected a
right hippocampal T2-hyperintensity 4 months later cor-
responding to progressive cognitive deficits (memory, ex-
ecutive functions) and generalized seizures, patient 4 did
not show MRI lesions.
After first line treatments, two patients received a con-
tinuous oral steroid therapy, while patient 3 was treated
with cyclophosphamide at mRS of 3. In most patients
clinical outcome at the last follow up after 9–31 months
(mRS median 0.5, interquartile range 0.25-2.5, n = 4)
was good with mRS 0–1 (3/4).Group analyses of brain glucose metabolism
In comparison to the matched reference group FDG-
PET of patients with anti-NMDA receptor encephalitis
(Figures 2A, 3A) displayed a regionally limited hyperme-
tabolism of bitemporal areas including hippocampus and
parahippocampus (99–439 voxels within Brodmann areas
20, 21, 22, 30, 35, 36, 48, Table 3) as well as an extensive
hypometabolism in the precuneus, the pre- and postcen-
tral, the parietal and posterior cingulate cortex (503–
1821 voxels within Brodmann areas 2, 3, 4, 6, 7, 17, 23, 26,
29, 30, 40, 43, Table 4). In patients with anti-LGI1 enceph-
alitis (Figures 2B, 3B) we observed hypermetabolism in
the cerebellum, basal ganglia as well as in precentral and
Figure 2 18F-fluoro-2-deoxy-d-glucose positron emission tomography in patients with anti-N-methyl-D-aspartate receptor and
anti-leucine rich glioma inactivated 1 protein encephalitis – tomographic display. Group analysis by statistical parametrical mapping of
18F-fluoro-2-deoxy-d-glucose positron emission tomography shows significant (p < 0.005, two sample t-test uncorrected for multiple comparisons
and an extent threshold of 30 voxels) hypermetabolism and hypometabolism in different brain regions of investigated patients with anti-N-
methyl-D-aspartate receptor encephalitis (A, anti-NMDA, n = 6) and anti-leucine rich glioma inactivated 1 protein encephalitis (B, anti-LGI1, n = 4)
compared to age and sex matched controls (n = 5–6). A, Clusters of significant voxels projected onto magnet resonance tomograms in Montreal
Neurological Institute space illustrate the typical pattern of temporomesial hippocampal and parahippocampal hypermetabolism as well as
widespread hypometabolism in the precuneus, pre- and postcentral, parietal and posterior cingulate cortex of anti-N-methyl-D-aspartate receptor
encephalitis patients. B, In anti-leucine rich glioma inactivated 1 protein encephalitis we observed hypermetabolism in the cerebellum, basal
ganglia, precentral and occipital areas and hypometabolism limited to the anterior cingulate / frontomesial cortex. C, Direct comparison of
anti-N-methyl-D-aspartate and anti-leucine rich glioma inactivated 1 protein encephalitis patients revealed hypometabolism in the precuneus,
parietal, occipital and cingulate cortex and hypermetabolism limited to frontotemporal regions. Significant hypermetabolism is indicated by red
to yellow and hypometabolism by blue to green color-coding.
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tamen, pallidum and within Brodmann areas 6, 8, 17, 18,
19, Table 4) and hypometabolism limited to the anterior
cingulate/frontomesial cortex (232 voxels within Brodmann
areas 10, 11, 24, 32, Table 4). Brain regions and Brodmann
areas showing significant abnormalities of glucose me-
tabolism in patients with anti-LGI1 and anti-NMDA
receptor encephalitis are summarized in Table 3 and
Table 4. The results of SPM analysis for each individual
patient are displayed in the supplemental material
(Additional files 2 and 3: Figures S1 and S2 and Additional
file 4: Table S2).
Direct comparison between the above mentioned types
of encephalitis likewise revealed distinct patterns with a
relative hypometabolism in the precuneus, precentral,parietal, occipital and cingulate cortex (338–2616 voxels
within Brodmann areas 2, 3, 4, 5, 6, 7, 10, 19, 20, 23, 26,
30, 39, 40) as well as regionally limited hypermetabolism
in frontotemporal areas (40–449 voxels within Brodmann
areas 10, 11, 20, 21, 22, 25, 30, 36, 38, 47, 48) of anti-
NMDA receptor encephalitis patients compared to the
anti-LGI1 associated syndrome (Figures 2C, 3C).
In LGI1-patients the mRS at follow up showed a posi-
tive correlation with the precentral metabolism (i.e. in-
creasing mRS values with increasing frontal metabolism
left, r = 0.95, p = 0.048). Other assessments for correla-
tions between brain metabolism and NMDA-/LGI1-
antibody titers in serum/CSF or the mRS at follow
up did not reveal consistent results of SPM and VOI
analyses.
Figure 3 18F-fluoro-2-deoxy-d-glucose positron emission tomography in patients with anti-N-methyl-D-aspartate receptor and
anti-leucine rich glioma inactivated 1 protein encephalitis – projection onto surface display. Group analysis by statistical parametrical
mapping of 18F-fluoro-2-deoxy-d-glucose positron emission tomography in patients with anti-N-methyl-D-aspartate receptor (anti-NMDA, n = 6)
and anti-leucine rich glioma inactivated 1 protein encephalitis (anti-LGI1, n = 4) displays significant (p < 0.005, two sample t-test uncorrected for
multiple comparisons and an extent threshold of 30 voxels) hypermetabolism and hypometabolism in different brain regions compared to
matched controls (n = 5–6). A, Clusters of significant voxel projected onto magnet resonance based images of the brain surface demonstrate
regionally limited hypermetabolism in frontotemporal areas contrasting extensive hypometabolism in parietal lobes of anti-N-methyl-D-aspartate
receptor encephalitis. B, In anti-leucine rich glioma inactivated 1 protein encephalitis hypermetabolism is predominant in the cerebellum, basal
ganglia, the occipital and precentral cortex whereas hypometabolism is restricted to the anterior cingulate/frontomesial cortex. C, Direct
comparison between anti-N-methyl-D-aspartate receptor and anti-leucine rich glioma inactivated 1 protein encephalitis patients reveals distinct
patterns of extensive hypometabolism in the precuneus, the parietooccipital and posterior cingulate cortex as well as hypermetabolism in
frontomesial and temporal areas. Significant hypermetabolism is indicated by red and hypometabolism by blue color coding.
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This retrospective study showed distinct brain metabolic
patterns in FDG-PETs of anti-LGI1 and anti-NMDA recep-
tor encephalitis patients. Analysis of the anti-LGI1 group
revealed hypermetabolism in cerebellar, basal ganglia, oc-
cipital and precentral regions and hypometabolism limited
to the anterior cingulate/frontomesial cortex, whereas in
anti-NMDA receptor encephalitis we found hypermetabo-
lism in frontotemporal areas and widespread hypometabo-
lism in parietal lobes.
The imaging results for anti-NMDA receptor enceph-
alitis patients are in agreement with a recent FDG-PET
study demonstrating frontotemporal hypermetabolism
and occipital hypometabolism [23] despite considerable
methodological differences. Our anti-NMDA receptor
encephalitis patients with mRS ≥ 4 at the time of PET
(n = 5) had to receive propofol narcosis during the
whole-body tumor scan to prevent severe artifacts by
involuntary movements, while Leypoldt et al. managed
imaging acquisition in patients showing similar initial
mRS (median 4.5) without sedation or narcosis (F. Leypoldt,
personal communication).The tracer FDG is taken up by active brain neurons as if
it was glucose and is then metabolized in the cells to FDG-
6-phosphate emitting radioactivity that can be measured
using PET. Uptake and metabolic trapping of FDG in the
brain as FDG-6-phosphate is completed to 80–90% 32 mi-
nutes after the intravenous injection [29]. In an FDG-PET
study with healthy volunteers receiving narcosis 25 min be-
fore FDG administration and during PET scanning, the re-
gional glucose metabolic rate was reduced during propofol
anaesthesia in all brain areas to 48–66% (p < 0.01) with
highest significant reductions in the occipital lobe, the lin-
gual gyrus, parietal lobe, temporal lobe and thalamus [30].
Although we applied FDG one hour before initiation of
narcosis and PET scanning, we cannot completely rule out
a minor hypometabolic propofol effect on brain metabolism
particularly in temporal and parietal areas of our anti-
NMDA receptor encephalitis patients. In most affected
temporal regions including hippocampus and parahip-
pocampus an underestimation of encephalitis-induced
hypermetabolism due to propofol narcosis seems possible.
In previous FDG-PETs without sedation or narcosis, fron-
totemporal hypermetabolism was more pronounced in
Table 3 18F-fluoro-2-deoxy-d-glucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis
patients
Hypermetabolism Hypometabolism
Hippocampus, parahippocampal, temporal sup., fusiform gyrus left Precuneus bilat., post. + mid. cingulum bilat., cuneus, calcarine left
(439 voxels in BA 20, 30, 35, 36, 48) (1821 voxels in BA 7, 17, 23, 26, 29, 30)
Hippocampus, parahippocampal right Parietal superior, precuneus bilat.
(264 voxels in BA 20, 30, 35, 36) (896 voxels in BA 5, 7)
Temporal sup., mid. right Parietal sup. bilat., precuneus bilat. parietal inf., postcentral right
(99 voxels in BA 20, 21, 22, 48) (720 voxels in BA 2, 3, 5, 7, 40)
Frontal inf., operculum, Insula right Pre-, postcentral, frontal mid. left
(57 voxels in BA 6, 48) (503 voxels in BA 4, 6, 9, 43)
Gyrus rectus, frontal supra-orbital, left Frontal mid, sup. right
(47 voxels in BA 11) (149 voxels in BA 10, 11, 46, 47)
Cerebellum left Occipital mid., inf. lingual, left
(47 voxels) (145 voxels in BA 18, 19)
Parietal supramarginal, inf. right
(93 voxels in BA 40)
Parietal supramarginal, temporal sup., mid. left
(77 voxels in BA 22)
Postcentral left
(73 voxels in BA 1, 2 ,3 ,4)
Frontal sup. left, suppl. mot. area bilat.
(60 voxels in BA 6)
Temporal inf., mid. right
(48 voxels in BA 20, 37)
Abbreviations: Brodmann area (BA).
Brain regions and Brodmann areas displaying significant abnormalities of glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography of
patients with anti-N-methyl-D-aspartate receptor encephalitis (n = 6, p < 0.005, two sample t-test uncorrected for multiple comparisons and an extent threshold of
30 voxels) compared to age and sex matched controls (n = 5).
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suggesting a minor hypometabolic propofol effect in these
brain areas of our patients.
VGKC-complex positive encephalitis patients without
LGI1 antibodies compose a more heterogenous group
than patients with LGI1 encephalitis. In a recent PET
study [31], only 1/7 VGKC-positive patients also showed
autoantibodies against LGI1 leading to hypometabolism in
the association cortices. In the remaining six patients, two
scans were rated as normal and four showed different
findings mostly involving the basal ganglia [31] suggesting
a heterogeneous pattern of brain glucose metabolism in
the VGKC-positive subtypes of limbic encephalitis. In pre-
vious case reports, the FDG-PETs in encephalitis patients
with autoantibodies against the VGKC-complex – LGI1
antibodies were not determined – indicated bilateral tem-
poromesial hypermetabolism and/or temporal hypometa-
bolism depending on the course of the disease [32-35].
The glycoprotein LGI1 is secreted from presynaptic
terminals and associates with synaptic Kv1 VGKCs [36].
LGI1 is highly expressed in the hippocampus and theneocortex, and mutations in the LGI1 gene cause auto-
somal dominant lateral temporal lobe epilepsy [13,37,38].
LGI1 antibodies have been detected predominantly in lim-
bic encephalitis, epilepsy and few patients with Morvan’s
disease [5,13,36]. Furthermore, LGI1 antibodies were de-
tected in a glutamic acid decarboxylase antibody-positive
patient suffering from progressive encephalomyelitis with
rigidity and myoclonus (PERM) [39].
Recent case reports demonstrated hypermetabolism in
the basal ganglia as well as in the left hippocampus and
amygdala in two patients 3–8 months after clinical onset of
encephalitis associated with LGI1-antibodies [17,40]. Very
lately Shin et al. demonstrated temporal and bilateral basal
ganglia hypermetabolism in 7/10 anti-LGI1 encephalitis pa-
tients (3 days to 2 years between symptom onset and diag-
nosis), which had not been compared to a matched control
group [24], suggesting that the anti-LGI1-induced brain
metabolic pattern may depend on the disease course, time
point of diagnosis/therapy initiation and treatment regimen.
Our anti-LGI1 patients were investigated without pro-
pofol narcosis by FDG-PET 1–12 months after clinical
Table 4 18F-fluoro-2-deoxy-d-glucose positron emission tomography in patients with anti-leucine rich glioma
inactivated 1 protein encephalitis
Hypermetabolism Hypometabolism
Cerebellum, bilat. Cingulum ant. bilat., mid. frontal sup. med., med. orbital right
(2286 voxels) (232 voxels in BA 10, 11, 24, 32)
Putamen, pallidum right
(322 voxels)
Precentral, frontal mid., sup. right
(210 voxels in BA 6, 8)
Putamen, pallidum left
(191 voxels)
Occipital inf., mid., calcarine right
(191 voxels in BA 17, 18, 19)
Parietal supramarginal, angular, temporal sup. right
(155 voxels in BA 22, 40, 48)
Calcarine, occipital mid., sup. left
(149 voxels in BA 17)
Paracentral lobule, precuneus left
(56 voxels in BA 2, 4, 5)
Temporal inf. left
(37 voxels in BA 20, 37)
Abbreviations: Brodmann area (BA).
Brain regions and Brodmann areas displaying significant abnormalities of glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography of
patients with anti-leucine rich glioma inactivated 1 protein encephalitis (n = 4, p < 0.005, two sample t-test uncorrected for multiple comparisons and an extent
threshold of 30 voxels) in comparison to matched controls (n = 6).
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areas, whereas hypermetabolic activity was most pro-
nounced in cerebellar, basal ganglia, occipital and precen-
tral regions. Interestingly, the precentral hypermetabolism
correlated positively with the mRS at follow up suggesting
that increased metabolism in this area may represent a
negative prognostic factor in LGI1 patients. The anti-LGI1
metabolic pattern contrasts the PET results of patients
with anti-NMDA receptor encephalitis underlining these
two etiologically different subtypes of autoimmune limbic
encephalitis. In addition to the autoantibody detection
as most important diagnostic feature, FDG-PET may
prove to be a useful imaging tool, besides whole-body
tumor search, for differentiating these subtypes of lim-
bic encephalitis.
Two distinct brain metabolic patterns in immunologic-
ally mostly undefined (7/9) limbic encephalitis patients
have been described in a recent FDG-PET study [41]. Five
younger patients including the two NMDA-receptor anti-
body positive cases displayed a mixed metabolic pattern
characterized by hypermetabolism in the temporal and
orbitofrontal cortex as well as occipital hypometabolism.
While this pattern in younger patients reminds of brain
metabolic changes seen in limbic encephalitis induced
by NMDA receptor IgG-antibodies [23], four olderpatients presented with subacute cognitive decline show-
ing diffuse cortical hypometabolism closely resembling
Alzheimer’s disease or dementia with Lewy Bodies [41].
This neurodegenerative-like hypometabolism is neither
likely to reflect the cognitive decline induced by NMDA
receptor IgA-antibodies leading to occipital hypermetabo-
lism [42] nor the anti-LGI1 syndrome where Shin et al.
and we found predominantly hypermetabolic changes.Conclusions
In conclusion, our retrospective FDG-PET study provides
novel evidence for distinct brain metabolic patterns in
patients with anti-LGI1 and anti-NMDA receptor enceph-
alitis. In anti-NMDA receptor encephalitis the regionally
limited hypermetabolism in frontotemporal areas con-
trasted extensive hypometabolism in parietal lobes, whereas
the anti-LGI1 syndrome is characterized by hypermetabo-
lism in cerebellar, basal ganglia, occipital and precentral
areas and minor frontomesial hypometabolism.Ethical standard
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